Protalix BioTherapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€53.37M - Cost of goods sold
€22.67M - Gross profit
€30.70M - SG&A expenses
€9.32M - R&D expenses
€14.29M - EBITDA
€9.09M - D&A
€1.18M - EBIT
€7.09M - Interest expenses
€942.53K - EBT
€6.97M - Tax expenses
€1.56M - Net income
€5.41M
Cash flow statement
- Net deferred tax
€483.33K - Non-cash items
€4.72M - Changes in working capital
-€15.61M - Operating cash flow
-€1.89M - Capex
€1.08M - Other investing cash flow
€4.74M - Net investing cash flow
€3.67M - Total cash dividends paid
€0.00 - Issuance of common stock
€8.99M - Debt repayment
€0.00 - Other financing cash flow
-€15.55M - Net financing cash flow
-€6.56M - Foreign exchange effects
€41.35K - Net change in cash
-€4.74M - Cash at end of period
€15.42M - Free cash flow
-€815.03K
Balance sheet
- Cash and cash equivalents
€15.42M - Cash and short-term investments
€28.77M - Total receivables
€8.14M - Inventory
€18.21M - Other current assets
€1.30M - Total current assets
€56.42M - Property, plant & equipment
€8.39M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€448.01K - Total non-current assets
€11.20M - Total assets
€67.62M - Accounts payable
€5.76M - Short-term debt
€1.27M - Other current liabilities
€10.50M - Total current liabilities
€20.76M - Long-term debt
€3.34M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€529.85K - Total non-current liabilities
€3.87M - Total liabilities
€24.63M - Common stock
€68.92K - Retained earnings
-€328.98M - Other equity
€0.00 - Total equity
€42.99M - Total liabilities and shareholders' equity
€67.62M
Company information
- Market capitalization
€104.57M - Employees
213 - Enterprise Value
€110.76M
Company ratios
- Gross margin
-
57.5% Much better than peer group: -1,529.5% - EBITDA margin
-
17.0% Much better than peer group: -5,505.5% - EBIT margin
-
13.3% Much better than peer group: -5,672.4% - EBT margin
-
13.1% Much better than peer group: -5,924.2% - Net margin
-
10.1% Much better than peer group: -5,387.3% - ROE
-
12.6% Much better than peer group: -3,627.0% - ROA
-
8.0% Much better than peer group: -276.1% - Asset turnover
-
78.9% Much worse than peer group: 341,779.9% - FCF margin
-
-5.6% Much better than peer group: -5,196.7% - FCF yield
-2.8% - Efficiency ratio
83.0% - Net sales per employee
-
€250.57K - Net income per employee
-
€25.38K